HARBIN, China, Dec. 29 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it was awarded Science and Technology Prize by Shandong Province for its Naftopidil Dispersible Tablet, a new drug developed by its wholly-owned subsidiary Peng Lai Jin Chuang Pharmaceutical Company (Jin Chuang).
Naftopidil Dispersible Tablets are intended for the treatment of enlarged prostate in men and can be easily absorbed and digested by the human body. Jin Chuang has taken five years to research and develop the Naftopidil Dispersible Tablet. Currently, the tablet can only be produced by Jin Chuang and it is expected to be launched in China early 2009.
"China Sky One Medical is honored to receive such a prestigious award which was widely recognized throughout China," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "In China, there is a huge potential market for drugs that treat enlarged prostate in men and we forecast that the sales of Naftopidil Dispersible Tablets will help us achieve higher revenues in 2009."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact: Company Contact: China Sky One Medical, Inc. Mr. Yu-Bo Hao, CFO Tel: +86-451-5399-4069 Email: firstname.lastname@example.org Investor Relations Contact: CCG Investor Relations Mr. Crocker Coulson, President Tel: +1-646-213-1915 Email: email@example.com Web: http://www.ccgirasia.com
|SOURCE China Sky One Medical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved